Endocrine-Resistant HR-Positive Metastatic Breast Cancer — An Interview with Dr Hope S Rugo on Optimal Management (Companion Faculty Lecture)

Featuring a slide presentation and related discussion from Dr Hope S Rugo, including the following topics:

Current treatment landscape for and outcomes in HR-positive, HER2-negative metastatic breast cancer (mBC) (0:00)

Trastuzumab deruxtecan for HER2-low and HER2-ultralow mBC (7:49)

Sacituzumab govitecan for HR-positive, HER2-negative mBC (20:44)

Datopotamab deruxtecan for HR-positive, HER2-negative mBC (27:29)

Novel antibody-drug conjugates under investigation for HR-positive mBC (33:19)

CME information and select publications

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.